Overcoming Obstacles to MASH Diagnosis and Management
Clinical Resources Center
Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis.
Aminian A, Aljabri A, Wang S, et al. Nat Med. 2025;31(3):988-995.
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.
Harrison SA, Bedossa P, Guy CD, et al. N Engl J Med. 2024;390(6):497-509.
Tirzepatide once weekly for the treatment of obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216.
Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups.
Li M, Chen W, Deng Y, et al. Nutr Metab Cardiovasc Dis. 2024;34(9):2085-2094.
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.
Loomba R, Hartman ML, Lawitz EJ, et al. N Engl J Med. 2024;391(4):299-310.
A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.
Newsome PN, Buchholtz K, Cusi K, et al. N Engl J Med. 2021;384(12):1113-1124.
Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH/NASH and moderate to noncirrhotic advanced fibrosis.
Noureddin M, Charlton MR, Harrison SA, et al. Clin Gastroenterol Hepatol. 2024:S1542-3565(24)00667-0.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, et al. Hepatology. 2023;78(6):1966-1986.
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
Sanyal AJ, Foucquier J, Younossi ZM, et al. J Hepatol. 2023;78(2):247-259.
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis.
Sanyal AJ, Newsome PN, Kliers I, et al. N Engl J Med. 2025;392(21):2089-2099.
Once-weekly semaglutide in adults with overweight or obesity.
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002.
Epidemiology of metabolic dysfunction-associated steatotic liver disease.
Younossi ZM, Kalligeros M, Henry L. Clin Mol Hepatol. 2025;31(suppl):S32-S50.
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis.
Younossi ZM, Stepanova M, Racila A, et al. Hepatology. 2025;81(4):1318-1327.
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.
Chen VL, Morgan TR, Rotman Y, et al. Hepatology. 2025;81(1):312-320.
2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery.
Eisenberg D, Shikora SA, Aarts E, et al. Surg Obes Relat Dis. 2022;18(12):1345-1356.
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. Hepatology. 2023;77(5):1797-1835.
AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
Sterling RK, Duarte-Rojo A, Patel K, et al. Hepatology. 2025;81(2):672-724.
Clinical Resources
A CLINICIAN GUIDE TO MASH DIAGNOSIS AND MANAGEMENT
Fibrosis-4 (FIB-4) index for liver fibrosis.
Resmetirom prescribing information.
US Food and Drug Administration.
Overcoming Obstacles to MASH Diagnosis and Management
A Clinical Obstacles Challenge
| Faculty: | Naim Alkhouri, MD, FAASLD, DABOM |
| Release: | 06/30/2025 |
| Expiration: | 06/30/2026 |
